Integra LifeSciences (IART) Reports In-Line Q1 EPS; revenue beat; offers guidance

Integra LifeSciences (NASDAQ: IART) reported Q1 EPS of $0.74, in-line with the analyst estimate of $0.74. Revenue for the quarter came in at $380.8 million versus the consensus estimate of $373.21 million.

GUIDANCE:

Integra LifeSciences sees Q2 2023 EPS of $0.75-$0.79, versus the consensus of $0.85. Integra LifeSciences sees Q2 2023 revenue of $396-400 million, versus the consensus of $404.8 million.

Integra LifeSciences sees FY2023 EPS of $3.43-$3.51, versus the consensus of $3.48. Integra LifeSciences sees FY2023 revenue of $1.6-1.62 billion, versus the consensus of $1.61 billion.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Integra LifeSciences Announces Key Executive Appointments
• BofA lists top 5 themes driving next $1tn in incremental semi sales